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Outcomes and Risk Factors Associated With SARS-CoV-2 Infection
in a North American Registry of Patients With Multiple Sclerosis
Amber Salter, PhD; Robert J. Fox, MD; Scott D. Newsome, DO; June Halper, MSCN; David K. B. Li, MD; Pamela Kanellis, PhD;
Kathleen Costello, MSCN; Bruce Bebo, PhD; Kottil Rammohan, MD; Gary R. Cutter, PhD; Anne H. Cross, MD
Supplemental content
IMPORTANCE Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather

information on clinical outcomes and risk factors associated with morbidity and mortality in
patients with multiple sclerosis (MS) and concomitant SARS-CoV-2 infections.
OBJECTIVE To examine outcomes and risk factors associated with COVID-19 clinical severity in

a large, diverse cohort of North American patients with MS.
DESIGN, SETTING, AND PARTICIPANTS This analysis used deidentified, cross-sectional data on
patients with MS and SARS-CoV-2 infection reported by health care professionals in North
American academic and community practices between April 1, 2020, and December 12,
2020, in the COVID-19 Infections in MS Registry. Health care professionals were asked to
report patients after a minimum of 7 days from initial symptom onset and after sufficient time
had passed to observe the COVID-19 disease course through resolution of acute illness or
death. Data collection began April 1, 2020, and is ongoing.
EXPOSURES Laboratory-positive SARS-CoV-2 infection or highly suspected COVID-19.
MAIN OUTCOMES AND MEASURES Clinical outcome with 4 levels of increasing severity: not
hospitalized, hospitalization only, admission to the intensive care unit and/or required
ventilator support, and death.
RESULTS Of 1626 patients, most had laboratory-positive SARS-CoV-2 infection (1345
[82.7%]), were female (1202 [74.0%]), and had relapsing-remitting MS (1255 [80.4%]). A
total of 996 patients (61.5%) were non-Hispanic White, 337 (20.8%) were Black, and 190
(11.7%) were Hispanic/Latinx. The mean (SD) age was 47.7 (13.2) years, and 797 (49.5%) had 1
or more comorbidity. The overall mortality rate was 3.3% (95% CI, 2.5%-4.3%). Ambulatory
disability and older age were each independently associated with increased odds of all clinical
severity levels compared with those not hospitalized after adjusting for other risk factors
(nonambulatory: hospitalization only, odds ratio [OR], 2.8 [95% CI, 1.6-4.8]; intensive care
unit/required ventilator support, OR, 3.5 [95% CI, 1.6-7.8]; death, OR, 25.4 [95% CI, 9.3-69.1];
age [every 10 years]: hospitalization only, OR, 1.3 [95% CI, 1.1-1.6]; intensive care unit/required
ventilator support, OR, 1.3 [95% CI, 0.99-1.7]; death, OR, 1.8 [95% CI, 1.2-2.6]).
CONCLUSIONS AND RELEVANCE In this registry-based cross-sectional study, increased

disability was independently associated with worse clinical severity including death from
COVID-19. Other risk factors for worse outcomes included older age, Black race,
cardiovascular comorbidities, and recent treatment with corticosteroids. Knowledge of these
risk factors may improve the treatment of patients with MS and COVID-19 by helping
clinicians identify patients requiring more intense monitoring or COVID-19 treatment.
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A

t the beginning of the COVID-19 pandemic caused by
SARS-CoV-2, many concerns regarding the risk of infection and its consequences were raised, spurring
global efforts to gather information.1,2 Multiple sclerosis (MS)
is a common central nervous system disease, with estimated
prevalence of 914 000 in the US and 90 000 in Canada.3,4 Because MS involves the immune system and MS diseasemodifying therapies (DMTs) alter the immune response, special concerns existed regarding the severity of COVID-19 in
patients with MS and the possible effects of MS DMTs on
COVID-19 outcomes.
Risk factors for poorer outcomes that have been identified
in the general population include older age, male sex, having
specific comorbid conditions, and select race/ethnicity.5-7 Early
reports with considerably smaller sample sizes indicated that
in patients with MS, age and disability were associated with a
more severe course of COVID-19.1,8,9 Larger definitive studies
have been needed to further understand the effect of comorbidities and patient characteristics.
The COVID-19 Infections in MS (COViMS) Registry is a North
American registry set up early in the pandemic for health care
professionals to report cases of SARS-CoV-2 infection in people
with MS and related conditions. Its goal is to understand how
people with MS fare on exposure to the virus and to identify
factors that might be associated with COVID-19 outcomes. To
enable ease of information sharing, COViMS Registry data collection was harmonized with the Global Data Sharing initiative acquiring information on SARS-CoV-2 infection worldwide. While similar strategies were used across the Global Data
Sharing initiative, North American–specific variations in SARSCoV-2 infections merit examination.10 Here, using data from
the COViMS Registry, we investigated factors associated with
severe outcomes in a large and diverse population of North
Americans with MS and SARS-CoV-2 infection.

Methods
The COViMS Registry collects data from health care professionals in North America and is jointly supported by the Consortium of Multiple Sclerosis Centers, National MS Society (US),
and MS Society of Canada. Broad outreach using a variety of
mediums to inform the neurologic community was conducted by the sponsoring organizations to enhance robustness and representativeness of data collected.

Study Design
Patients with MS and laboratory-positive or highly suspected
infection with SARS-CoV-2 were eligible for inclusion in the
COViMS Registry. Health care professionals were asked to report patients after a minimum of 7 days from initial infectious symptom onset and when sufficient time had passed to
observe the COVID-19 disease course through resolution of
acute illness or death. COVID-19 diagnosis in laboratoryconfirmed patients was based on either polymerase chain reaction or serology tests. The data collection instrument was
developed by a group of MS clinicians and epidemiologists and
harmonized with the Global Data Sharing initiative COVID-19
700

Key Points
Question How do patients with multiple sclerosis (MS) who have
COVID-19 fare and are there patient and disease characteristics
associated with worse outcome?
Findings In this registry-based cross-sectional study of 1626
North American patients with MS and COVID-19 infection,
ambulatory disability, both nonambulatory and requiring
assistance to walk, was independently associated with increased
odds of poor clinical severity levels after adjusting for other risk
factors. Other factors including older age, male sex, Black race,
cardiovascular comorbidities, and corticosteroid use in the past 2
months were associated with increased odds of increasing clinical
severity compared with those not requiring hospitalization or
worse.
Meaning Identification of risk factors can improve the treatment
of patients with MS and COVID-19 by alerting clinicians of patients
requiring more intense treatment or monitoring.

core data set11 when possible. The instrument was designed
to answer the main questions but to be brief to minimize the
time to enter data during this crisis. Starting April 1, 2020, deidentified, cross-sectional patient-level data were entered into
a secure, Health Insurance Portability and Accountability Act–
compliant web-based REDCap12 database housed at Washington University in St Louis. Research participant protection was
sought from the Washington University in St Louis institutional review board for housing COViMS Registry data, who determined it to be not human subjects research and therefore
exempt from active institutional review board oversight at
Washington University in St Louis and did not require patient
consent. Individual contributors were encouraged to confer
with their local institutional review board regarding requirements. Data use agreements govern the use of some data that
were contributed, and thus access to individual-level data are
not permitted by outside researchers. This study followed
the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline.

Risk Factors
Demographic risk factors collected were sex (male, female,
nonbinary), age, race (White; Black or African American [Black];
Asian; American Indian, Alaska Native, or Indigenous Canadian; Native Hawaiian or other Pacific Islander; other; or
unknown), ethnicity (Hispanic or Latinx, not Hispanic or
Latinx, other, or unknown), and country and state/province
at time of infection.
MS disease characteristics collected include MS disease
duration and ambulation milestones (fully ambulatory, walks
with assistance, nonambulatory). Comorbid conditions were
selected from cancer, cardiovascular disease, cerebrovascular
disease, chronic kidney disease, chronic liver disease, chronic
lung disease, chronic neurological and/or neuromuscular disease, diabetes, hypertension, immunodeficiency disease,
morbid obesity, and other. Comorbid conditions were also
summed to categorize the count as 0 (reference), 1, 2, and 3 or
more comorbidities. Cigarette use history was captured as
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never, past, current, or unknown. Glucocorticoid treatment during the prior 2 months was ascertained. Current DMT at the time
of SARS-CoV-2 infection was reported as one of the following: alemtuzumab, azathioprine, cladribine, daclizumab, dimethyl fumarate, diroximel fumarate, fingolimod, glatiramer acetate, hematopoietic stem cell transplant, interferon-beta, intravenous
immunoglobulin, methotrexate, mitoxantrone, mycophenolate,
natalizumab, ocrelizumab, ofatumumab, ozanimod, rituximab,
siponimod, teriflunomide, other, none, and unknown.
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outcomes, including only laboratory-positive cases and the
number of comorbid conditions using similar methodology.
Statistical analyses were conducted using SAS statistical software version 9.4 (SAS Institute Inc). Two-sided P values were
statistically significant at .05.

Results
Population

Outcome
Clinicians summarized events of the COVID-19 course by indicating whether the patient was hospitalized, admitted to the
intensive care unit (ICU), required ventilator support, or died,
with response options of yes, no, or unknown to each. Responses of unknown were considered as not having the outcome. These events were used to create a single outcome of
severe COVID-19 with 4 levels of increasing severity: not hospitalized, hospitalization only, ICU and/or required ventilator
support, and death. If a patient had more than 1 of the events,
they were assigned to the highest level of event that occurred.13

Statistical Analysis
Cohort characteristics were summarized using mean (SD) for
continuous variables, median (interquartile range) for ordinal variables, and frequencies (%) for categorical variables.
Comparisons between groups were made using t tests and
χ2 or Fisher exact tests, as appropriate. Age- and race-specific
outcome proportions and 95% exact CIs were reported and
differences evaluated using a χ2 test. A Cochran-MantelHaenszel was used to evaluate differences across age and race
groups.
A multivariable multinomial logistic regression model
was constructed to examine the assocations of risk factors
with COVID-19 clinical severity with not hospitalized as the
reference level. The multinomial model was used after
detecting violations in the proportional odds assumption for
an ordinal logistic regression. The multivariable models
included a fixed set of covariates including age (continuous),
sex (reference, female), race (reference, White), ambulation
(reference, fully ambulatory), cigarette smoking history (reference, never smoked), glucocorticoid use (reference, no),
comorbidities, and DMTs. Comorbidities included were
cardiovascular disease, chronic lung disease, diabetes, hypertension, and morbid obesity (reference, absence of comorbidity [no]); current DMTs were categorized as none (reference),
interferons (interferon beta-1a, interferon beta-1b), glatiramer
acetate, fumarates (dimethyl fumarate, diroximel fumarate),
sphingosine 1-phosphate receptor modulators (fingolimod,
siponimod, ozanimod), teriflunomide, ocrelizumab, natalizumab, rituximab, and other (all <10 patients reported taking
the DMT: alemtuzumab, cladribine, intravenous immunoglobulin, azathioprine, methotrexate, mitoxantrone, mycophenolate, ofatumumab, other). Associations were reported
using odds ratios and 95% CIs. Multicollinearity was assessed
using the correlation matrix for the parameter estimates and
factors with associations more than 0.8 removed. Sensitivity
analyses were conducted to examine the associations with
jamaneurology.com

As of December 12, 2020, 1626 patients with MS were
reported in the COViMS Registry by more than 150 North
American academic and private practices in 47 US states,
Puerto Rico, 4 Canadian provinces, and Mexico (eFigure in the
Supplement). Demographic and clinical characteristics are
shown in Table 1. Most patients were laboratory positive (1345
[82.7%]), were female (1202 [74.0%]), had relapsing-remitting
MS (1255 [80.4%]), and were in the US at COVID-19 onset
(1547 [97.0%]). The mean (SD) age was 47.7 (13.2) years and
MS disease duration was 13.1 (9.9) years. Approximately half
had 1 or more comorbidity. Hypertension (358 [22.0%]), morbid obesity (179 [11.0%]), and diabetes (148 [9.1%]) were most
frequently reported.

COVID-19 Symptoms
Fewer than 55% (n = 878) reported fever as a symptom of
COVID-19. Dry cough and fatigue were each reported in about
40% of patients (637 [39.2%] and 657 [40.4%], respectively),
with shortness of breath in 30.3% (n = 492). Anosmia, ageusia, pain, and headache were each reported in approximately
25% of patients (423 [26%], 412 [25.3%], 416 [25.6%], and 418
[25.7%], respectively) (Figure 1). Neurological symptoms were
reported in 144 patients (8.9%). Of those with neurological
symptoms, 64 (44.4%) reported motor dysfunction, and 37
(25.7%) reported cognitive dysfunction. Eighty-five cases
(5.2%) were reported as asymptomatic. Symptoms lasted for
14 or more days in more than half of patients (0-6 days, 214
[20.8%]; 7-13 days, 285 [27.7%]; 14-20 days, 284 [27.6%]; and
≥21 days, 247 [24.0%]).

COVID-19 Outcomes
Regarding individual components of the outcome, 425
(26.1%) visited an emergency department, 320 (19.7%) were
hospitalized, 112 (6.9%) had pneumonia, 104 (6.4%) were
admitted to the ICU, and 61 (3.8%) required ventilator support. Overall mortality rate was 3.3% (n = 54; 95% CI, 2.5%4.3%). Of those who died, 43 (79.6%) were hospitalized, 29
(53.7%) were admitted to the ICU, and 25 (46.3%) required
ventilator support. Mortality increased with age (Figure 2A),
with no deaths in those younger than 35 years. The mortality
rate was 1.2% (95% CI, 0.4%-2.9%) for individuals aged 35 to
44 years, 2.1% (95% CI, 1.0%-4.0%) for those aged 45 to 54
years, 4.9% (95% CI, 2.8%-7.8%) for those aged 55 to 64 years,
11.7% (95% CI, 7.0%-18.1%) for those aged 65 to 74 years, and
22.6% (95% CI, 9.6%-41.1%) for those 75 years or older.
The mortality rate was 3.5% (95% CI, 2.5%-4.9%) for White
patients with MS, 4.2% (95% CI, 2.3%-6.9%) for Black patients with MS, and 1.1% (95% CI, 0.1%-3.8%) for Hispanic/
(Reprinted) JAMA Neurology June 2021 Volume 78, Number 6
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Table 1. Demographic and Clinical Characteristics Overall and by Clinical Outcome Severitya
No. (%)

Overall (N = 1626)

Not hospitalized
(n = 1293)

Hospitalization
only (n = 200)

ICU and/or
required
ventilator support
(n = 79)

Female

1202 (74.0)

985 (76.3)

132 (66.0)

57 (72.2)

28 (51.9)

Male

421 (25.9)

305 (23.6)

68 (34.0)

22 (27.8)

26 (48.1)

47.7 (13.2)

46.0 (12.7)

52.2 (12.9)

53.4 (12.5)

62.4 (11.9)

Characteristic
Sex

Age, mean (SD), y

Death (n = 54)

P value

<.001b
<.001c

Race/ethnicity
Non-Hispanic White

996 (61.5)

802 (62.4)

121 (60.5)

38 (48.1)

35 (64.8)

Black or African American

337 (20.8)

240 (18.7)

56 (28.0)

27 (34.2)

14 (25.9)

Hispanic or Latinx

190 (11.7)

161 (12.5)

16 (8.0)

11 (13.9)

2 (3.7)

Otherd/unknown

96 (5.9)

83 (6.5)

7 (3.5)

3 (3.8)

3 (5.6)

United States

1547 (97.0)

1224 (96.8)

193 (96.5)

76 (98.7)

54 (100.0)

Canada

30 (1.9)

27 (2.1)

3 (1.5)

0

0

Mexico

2 (0.13)

2 (0.16)

0

0

0

Other

16 (1.0)

11 (0.87)

4 (2.0)

1 (1.3)

0

Northeast

365 (23.7)

272 (22.3)

58 (30.1)

13 (17.6)

22 (40.7)

Midwest

367 (23.8)

298 (24.4)

36 (18.7)

22 (29.7)

11 (20.4)

South

671 (43.6)

552 (45.3)

74 (38.3)

29 (39.2)

16 (29.6)

West

137 (8.9)

97 (8.0)

25 (13.0)

10 (13.5)

5 (9.3)

Laboratory positive

1345 (82.7)

1035 (77.0)

186 (13.8)

75 (5.6)

49 (3.6)

Suspected COVID-19, not confirmed

281 (17.3)

258 (91.8)

14 (5.0)

4 (1.4)

5 (1.8)

13.1 (9.9)

12.2 (9.5)

15.1 (10.7)

16.9 (10.6)

21.3 (10.6)

RRMS/CIS

1275 (82.0)

1091 (87.6)

130 (66.7)

37 (54.4)

17 (36.2)

Progressive MS

280 (18.0)

154 (12.4)

65 (33.3)

31 (45.6)

30 (63.8)

Fully ambulatory

1184 (75.2)

1033 (82.0)

107 (54.3)

36 (50.7)

8 (17.0)

Walk with assistance

241 (15.3)

154 (12.2)

57 (28.9)

21 (29.6)

9 (19.1)

Nonambulatory

149 (9.5)

72 (5.7)

33 (16.8)

14 (19.7)

30 (63.8)

Alemtuzumab

9 (0.57)

6 (0.48)

1 (0.51)

1 (1.4)

1 (2.1)

Cladribine

14 (0.89)

13 (1.0)

1 (0.51)

0

0

Dimethyl fumarate

208 (13.3)

179 (14.3)

22 (11.1)

4 (5.6)

3 (6.3)

Diroximel fumarate

3 (0.19)

3 (0.24)

0

0

0

Fingolimod

106 (6.8)

97 (7.8)

3 (1.5)

6 (8.3)

0

Glatiramer acetate

84 (5.4)

70 (5.6)

12 (6.1)

0

2 (4.2)

Interferon beta

53 (3.4)

49 (3.9)

2 (1.0)

1 (1.4)

1 (2.1)

IVIG

6 (0.38)

6 (0.48)

0

0

0

Methotrexate

2 (0.13)

2 (0.16)

0

0

0

Mycophenolate

2 (0.13)

1 (0.08)

0

0

1 (2.1)

Natalizumab

170 (10.8)

154 (12.3)

12 (6.1)

1 (1.4)

3 (6.3)

Ocrelizumab

484 (30.9)

367 (29.4)

77 (38.9)

29 (40.3)

11 (22.9)

Ofatumumab

3 (0.19)

2 (0.16)

1 (0.51)

0

0

Ozanimod

1 (0.06)

1 (0.08)

0

0

0

Rituximab

77 (4.9)

48 (3.8)

19 (9.6)

7 (9.7)

3 (6.3)

Siponimod

17 (1.1)

11 (0.88)

4 (2.0)

0

2 (4.2)

Teriflunomide

82 (5.2)

69 (5.5)

8 (4.0)

2 (2.8)

3 (6.3)

Other

10 (0.64)

4 (0.32)

4 (2.0)

1 (1.4)

1 (2.1)

None

237 (15.1)

168 (13.4)

32 (16.2)

20 (27.8)

17 (35.4)

.001b

Country at time of COVID-19 onset

.68e

US census region

.001b

Type of COVID-19 diagnosis

Disease duration, mean (SD), y

<.001b
<.001c

MS clinical course
<.001b

Ambulatory status
<.001b

DMT at time of COVID-19

<.001b

(continued)
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Table 1. Demographic and Clinical Characteristics Overall and by Clinical Outcome Severitya (continued)
No. (%)

Characteristic
Glucocorticoid during the last 2 mo

Overall (N = 1626)

Not hospitalized
(n = 1293)

Hospitalization
only (n = 200)

ICU and/or
required
ventilator support
(n = 79)

Death (n = 54)

No

1333 (89.0)

1069 (90.1)

165 (85.1)

65 (91.5)

34 (75.6)

Yes

63 (4.2)

37 (3.1)

18 (9.3)

4 (5.6)

4 (8.9)

Unknown

101 (6.7)

81 (6.8)

11 (5.7)

2 (2.8)

7 (15.6)

P value

<.001b

Comorbidities
No

769 (47.7)

664 (51.9)

72 (36.2)

28 (35.9)

5 (9.3)

Yes

797 (49.5)

577 (45.1)

125 (62.8)

49 (62.8)

46 (85.2)

Unknown

45 (2.8)

39 (3.0)

2 (1.0)

1 (1.3)

3 (5.6)

Cancer

62 (3.8)

47 (3.6)

10 (5.0)

1 (1.3)

4 (7.4)

.24b

Cardiovascular disease

92 (5.7)

45 (3.5)

22 (11.0)

10 (12.7)

15 (27.8)

<.001b

Cerebrovascular disease

25 (1.5)

10 (0.77)

11 (5.5)

4 (5.1)

0

<.001b

Chronic kidney disease

19 (1.2)

9 (0.70)

2 (1.0)

2 (2.5)

6 (11.1)

<.001b

Chronic liver disease

12 (0.74)

8 (0.62)

0

1 (1.3)

3 (5.6)

<.001b

Chronic lung disease

116 (7.1)

78 (6.0)

20 (10.0)

13 (16.5)

5 (9.3)

.001b

Chronic neurological disease

79 (4.9)

51 (3.9)

14 (7.0)

8 (10.1)

6 (11.1)

.003b

<.001b

Diabetes

148 (9.1)

83 (6.4)

39 (19.5)

15 (19.0)

11 (20.4)

<.001b

Hypertension

358 (22.0)

244 (18.9)

60 (30.0)

26 (32.9)

28 (51.9)

<.001b

Immunodeficiency disease

34 (2.1)

21 (1.6)

6 (3.0)

3 (3.8)

4 (7.4)

.01b

Morbid obesity

179 (11.0)

122 (9.4)

31 (15.5)

17 (21.5)

9 (16.7)

<.001b

Other

245 (15.1)

185 (14.3)

28 (14.0)

9 (11.4)

23 (42.6)

<.001b

0

833 (51.2)

720 (55.7)

75 (37.5)

30 (38.0)

8 (14.8)

1

422 (26.0)

341 (26.4)

54 (27.0)

15 (19.0)

12 (22.2)

2

229 (14.1)

159 (12.3)

43 (21.5)

14 (17.7)

13 (24.1)

≥3

142 (8.7)

73 (5.6)

28 (14.0)

20 (25.3)

21 (38.9)

Comorbidity count

Abbreviations: CIS, clinically isolated syndrome; DMT, disease-modifying
therapy; ICU, intensive care unit; IVIG, intravenous immunoglobulin;
MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis.
a

Data not available for all individuals. Missing values: sex, 2; age, 16; race, 7;
country at time of COVID-19 onset, 31; census region, 7; disease duration, 96;
MS clinical course, 65; ambulatory status, 52; glucocorticoid during the last 2
months, 129; DMT at time of COVID-19, 58; have comorbidities, 15.

Latinx patients with MS. eTable 1 in the Supplement reports
the age- and race-specific rates for each level of clinical severity. Higher proportions of younger-aged Black patients with MS
had worse outcomes vs younger White patients (Figure 2B).
Clinical severity in 190 Hispanic/Latinx patients with MS was
generally similar to those of White patients with MS across age
levels.

Risk Factors
Compared with patients with MS who were not hospitalized,
older age was associated with an increased risk of each level
of COVID-19 severity after adjusting for covariates (Table 2).
For every 10-year increase in age, a 30% increased risk of both
hospitalization alone and ICU admission and/or ventilation was
identified. Notably, there was a 76.5% increased risk of death
for every 10-year age increase. Male sex was associated with
41% increased odds of hospitalization and more than 3-fold
increased risk of death. Black patients with MS had a 47%
increased odds of hospitalization alone, more than a 2-fold
jamaneurology.com

b

<.001b

Pearson χ2 test was used to determine the P value.

c

Analysis of variance was used to determine the P value.

d

Other races include Asian; American Indian, Alaska Native, or Indigenous
Canadian; and Native Hawaiian or other Pacific Islander.

e

Fisher exact test was used to determine the P value.

increased risk of ICU admission and/or ventilation, yet no
increased risk of death. No associations with poorer clinical
severity were observed in Hispanic/Latinx individuals and
other races.
Requiring assistance to walk or being nonambulatory was
independently associated with increased odds of all COVID-19
clinical severity levels after adjusting for covariates (Table 2).
Requiring assistance to walk was associated with 2-fold or
greater increased odds of all clinical severity levels. Being nonambulatory was associated with 2.8-fold increased odds of hospitalization alone and 3.5-fold increase for ICU admission
and/or ventilation. A 25-fold increased odds of death for nonambulatory patients with MS compared with fully ambulatory patients was observed after adjustment for other risk factors. Cardiovascular disease was associated with a 91%
increased risk of hospitalization alone and more than 3-fold
increased odds of death from COVID-19. Hypertension was also
associated with more than 3-fold increased risk of death but
not other levels of clinical severity. Diabetes was associated
(Reprinted) JAMA Neurology June 2021 Volume 78, Number 6

Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User on 09/15/2022

703

Research Original Investigation

SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis

with 2.5-fold increased odds of hospitalization but not other
levels of clinical severity. Morbid obesity was associated with
a 68.5% increased odds of hospitalization alone and an almost 3-fold increased odds of ICU admission and/or ventilation. No associations between COVID-19 clinical severity and
cigarette smoking and chronic lung disease were observed.
Compared with those not taking any DMT, patients taking rituximab had a 4.5-fold increased odds of hospitalization for COVID-19; however, no other levels of clinical severity were associated with taking rituximab. Ocrelizumab use
slightly increased the odds of hospitalization alone (odds ratio, 1.63). Fumarates and natalizumab treatments were each
associated with decreased odds of ICU admission and/or ventilation. Notably, glucocorticoid use in the prior 2 months conferred approximately 2-fold increased risk of hospitalization
and 4-fold increased risk of death.

Figure 1. Frequency of COVID-19 Symptoms for Each COVID-19
Clinical Severity Level
COVID-19 symptom
Fever

Fatigue

Dry cough

Shortness of breath

Other

Sensitivity Analyses
SARS-CoV-2–laboratory positive patients were older, had a
higher proportion of Black patients with MS, and more cardiovascular comorbidities compared with patients with suspected COVID-19 (eTable 2 in the Supplement). Analyses examining only the laboratory-positive patients showed risk
factors that were consistent with the entire cohort at all clinical severity levels (eTable 3 in the Supplement). Results for the
model including number of comorbidities were also consistent. Having 2 or more comorbid conditions was associated
with increased odds of poorer clinical outcome compared with
having no comorbidities (eTable 4 in the Supplement).

Anosmia (loss of smell)

Headache

Pain (joint, bone, muscle)

Ageusia (loss of taste)

Sore throat

Discussion
Chills

Diarrhea

Neurological

Nausea

Productive cough
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Patients with COVID-19, %

ICU indicates intensive care unit.
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The COViMS Registry collected clinician-reported information on COVID-19 outcomes and risk factors from a large, diverse set of patients with MS in North America. SARS-CoV-2
infection was laboratory confirmed in more than 82% of reported cases. Increased neurologic disability was consistently associated with a large increased risk of severe clinical
outcome after accounting for other risk factors. Although not
all statistically significant, rituximab showed notable and consistent associations with worse outcomes compared with other
DMTs. Older age, obesity, and several cardiovascular comorbidities were associated with more severe COVID-19 as well.
The COViMS Registry is uniquely positioned to explore the
association of race and ethnicity with COVID-19 outcomes,
which is of special interest in the diverse North American population. Compared with White race, Black race was associated
with increased odds of ICU admission and/or ventilation and
a nominally increased odds of hospitalization alone. However, no association of Black race with death from COVID-19
was observed in the COViMS Registry. Similarly, some studies in the general US population have not found increased mortality in Black patients with COVID-19 after adjustment for
other risk factors.14-16 We did not collect measures of socioeconomic or essential worker status, which might have contributed toward explaining racial and age differences. Yet, an
unmeasured confounder such as occupation or living condi-
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Figure 2. COVID-19 Clinical Severity Rates by Age and Race/Ethnicity
A Clinical severity rates of COVID-19 by age
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tions would need to impart a strong association, with an odds
ratio of 2.4 or more, between race and COVID-19 clinical outcome to account for the worse outcomes observed for Black
patients with MS compared with White patients with MS.17 Altogether, the worse outcomes observed for Black patients with
MS indicate that close clinical monitoring of COVID-19 in these
patients is warranted.
Compared with those not taking any DMT, rituximab use
was associated with an increased risk of hospitalization. Although the risk for hospitalization for ocrelizumab was nominally increased, the association was not as strong as with rituximab. Differences in associations with COVID-19 outcomes for
the 2 anti-CD20 monoclonal antibody therapies (rituximab and
ocrelizumab) could be due to longer treatment duration with
rituximab because ocrelizumab was more recently available. The
Italian MS and COVID-19 (MUSC-19) registry did not distinguish between anti-CD20 therapies but showed worse clinical
outcomes and higher risk with longer duration of anti-CD20
exposure.18 The COVID-19 Global Rheumatology Alliance registry found rituximab to be associated with 4-fold increased odds
of death in people with rheumatologic disease compared with
methotrexate-treated patients.19 While the French Covisep MS
registry reported no association of anti-CD20 therapies with
worse COVID-19 outcomes, its sample size of 347 may have limited the ability to detect associations.9 Taken together, these
studies suggest increased risks of COVID-19 in people treated
with rituximab.
The percent of COViMS Registry patients taking interferon beta and glatiramer acetate were 3.4% and 5.4%, respectively. Interestingly, the 2020 US market shares for interferon
beta (14.5%) and glatiramer acetate (18.9%) are much larger
than their proportions reported in the COViMS Registry. This
may reflect prescribing patterns of a nonrandom sample of clinician reporters or might indicate a true effect of these DMTs
on susceptibility to COVID-19. Notably, early data suggest a pojamaneurology.com

tential benefit for taking interferon beta on exposure to
SARS-CoV-220; currently, trials are underway to study the efficacy of interferon beta in COVID-19.21,22 In this study, fumarates and natalizumab were each associated with reduced risk
of ICU admission and/or ventilation compared with those not
receiving therapy. The reason for this is unknown but may be
associated with the relative anti-inflammatory vs immunosuppressive effects of these medications.
Similar to MUSC-1918 and data reported in rheumatoid arthritis studies, we found an association of recent glucocorticoid use with increased risk of hospitalization and mortality.23,24
This was not completely unexpected, as glucocorticoids affect
the immune system, reducing responsiveness to infections.
Glucocorticoids sometimes are prescribed to treat the inflammatory cytokine storm of COVID-19, so the timing of glucocorticoid administration and type of glucocorticoid could play a role
in COVID-19 outcomes.
With 54 deaths, we report the highest number of deaths thus
far in a registry of patients with MS, to our knowledge. All deaths
occurred in US patients. The COViMS Registry mortality rate of
3.3% was in line with the mortality rate reported by the Covisep MS registry (3.5%)9 but higher than the MUSC-19 cohort
(1.5%).18 The 3.3% mortality rate in the COViMS Registry was also
higher than the US mortality rate of 1.8% as of December 12,
2020.25 This may merely reflect greater tendency to report more
severe cases in the voluntary COViMS Registry; however, numerous societal and public health issues may have also contributed. Risk factors for mortality identified in the COViMS Registry were older age, male sex, and hypertension, consistent with
risk factors observed in the general population.26
No clear association of MS diagnosis with risk of developing COVID-19 could be established in this study because of the
unknown numbers at risk in the MS populations from whom
cases were reported. However, ambulatory disability from MS
was strongly associated with worse COVID-19 outcomes, con(Reprinted) JAMA Neurology June 2021 Volume 78, Number 6
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Table 2. Multivariable Multinomial Logistic Regression Model for the Clinical Severity Outcome
COVID-19 clinical course outcome levela

P value

ICU and/or required
ventilator support, OR
(95% CI)

P value

Death, OR (95% CI)

P value

<.001

1.29 (0.99-1.67)

.06

1.77 (1.20-2.59)

.004

1.41 (0.98-2.03)

.06

1.00 (0.54-1.83)

.99

3.12 (1.46-6.65)

.003

Non-Hispanic White

1 [Reference]

NAb

1 [Reference]

NAb

1 [Reference]

NAb

Black

1.47 (0.98-2.22)

.03

2.28 (1.22-4.23)

.08

1.60 (0.65-3.93)

.60

Hispanic or Latinx

0.77 (0.41-1.44)

.34

1.76 (0.76-4.09)

.50

0.57 (0.10-3.18)

.23

Otherc/unknown

0.82 (0.33-2.08)

.61

0.94 (0.20-4.36)

.50

2.95 (0.45-19.5)

.25

Fully ambulatory

1 [Reference]

NAb

1 [Reference]

NAb

1 [Reference]

NAb

Walk with assistance

2.18 (1.42-3.34)

.23

2.35 (1.22-4.54)

.48

3.14 (0.99-9.95)

.32

Nonambulatory

2.82 (1.64-4.85)

.01

3.53 (1.59-7.81)

.02

25.4 (9.34-69.1)

<.001

Risk factor

Hospitalization only,
OR (95% CI)

Age (every 10-y increase)

1.32 (1.12-1.56)

Sex (male vs female)
Race/ethnicity

Ambulation

Smoking status
Never

1 [Reference]

NAb

1 [Reference]

NAb

1 [Reference]

NAb

Current

1.09 (0.52-2.29)

.99

NAb

.95

2.88 (0.67-12.4)

.24

Past

1.08 (0.73-1.60)

.95

1.10 (0.61-1.99)

.95

1.32 (0.59-2.94)

.76

Unknown

1.22 (0.58-2.57)

.71

1.46 (0.48-4.45)

.94

1.23 (0.26-5.94)

.77

Cardiovascular disease (yes vs no)

1.91 (1.02-3.59)

.04

1.46 (0.54-3.98)

.46

3.15 (1.18-8.45)

.02

Chronic lung disease (yes vs no)

1.29 (0.71-2.36)

.41

2.12 (0.97-4.67)

.06

1.10 (0.30-4.05)

.89

Diabetes (yes vs no)

2.46 (1.50-4.04)

<.001

1.85 (0.87-3.95)

.11

1.07 (0.39-2.93)

.90

Hypertension (yes vs no)

1.11 (0.73-1.69)

.63

1.08 (0.58-2.04)

.80

3.14 (1.38-7.15)

.006

Morbid obesity (yes vs no)

1.69 (1.03-2.75)

.04

2.87 (1.48-5.54)

.002

2.49 (0.92-6.75)

.07

None

1 [Reference]

NAb

1 [Reference]

NAb

1 [Reference]

NAb

Fumarates

0.99 (0.52-1.88)

.90

0.26 (0.08-0.82)

.98

0.40 (0.09-1.70)

.30

S1PR

0.65 (0.26-1.61)

.23

0.77 (0.28-2.14)

.94

0.86 (0.15-4.93)

.89

Glatiramer acetate

1.15 (0.51-2.61)

.73

NAb

.96

0.86 (0.16-4.56)

.89

Interferons

0.35 (0.08-1.57)

.11

0.29 (0.04-2.32)

.98

0.56 (0.06-5.49)

.75

Natalizumab

0.67 (0.31-1.45)

.18

0.09 (0.01-0.73)

.98

0.80 (0.19-3.44)

.96

Ocrelizumab

1.63 (0.98-2.72)

.009

0.91 (0.46-1.80)

.94

0.47 (0.17-1.30)

.25

Other

1.21 (0.45-3.24)

.70

0.50 (0.10-2.38)

.96

0.91 (0.18-4.73)

.83

Rituximab

4.56 (2.10-9.90)

<.001

1.92 (0.61-6.07)

.91

2.81 (0.45-17.70)

.11

Teriflunomide

0.83 (0.34-2.02)

.58

0.30 (0.06-1.37)

.98

0.48 (0.08-3.04)

.57

No

1 [Reference]

NAb

1 [Reference]

NAb

1 [Reference]

NAb

Unknown

0.94 (0.46-1.92)

.16

0.44 (0.10-1.94)

.19

2.13 (0.68-6.72)

.95

Yes

2.62 (1.33-5.17)

.009

1.57 (0.49-4.97)

.21

4.17 (1.13-15.4)

.13

Disease-modifying therapy

Glucocorticoid use in past 2 mo

Abbreviations: ICU, intensive care unit; NA, not applicable; OR, odds ratio;
S1PR, sphingosine 1-phosphate receptor.
a

Reference level is not hospitalized.

sistent with other studies.8,9,23,27 We did not capture information on assocations of SARS-CoV-2 infection within MS itself. Although some neurologic symptoms were noted in association
with COVID-19, these symptoms were not prominent. Neurological symptoms have been reported in otherwise healthy
persons with COVID-19.28,29

Limitations
Limitations of this analysis include that reporting was voluntary by health care professionals, which may have biased
reporting toward more severe cases. This would overestimate
706

b

Insufficient sample size to estimate OR.

c

Other races include Asian; American Indian, Alaska Native, or Indigenous
Canadian; and Native Hawaiian or other Pacific Islander.

overall clinical severity in the COViMS Registry but have less
effect on the comparisons among risk factors. Although cases
were reported by more than 150 different sites spanning both
academic and community practices across North America, a
large proportion of COViMS Registry data, including 21 of 54
deaths, derived from the Northeast US. This was not unexpected given the disproportionate effect of COVID-19 on that
region early in the pandemic. The COViMS Registry is ongoing, and regional shifts are expected as the pandemic
expands within North America. Some patients may have
behaved more cautiously and adhered more strictly to public
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health recommendations because of MS, but this was not
captured.

Conclusions
With more than 1600 reported patients with MS, the COViMS
Registry provides evidence that ambulation disability, older
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